Hypoxanthine

DB04076

small molecule experimental

Deskripsi

Hypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.

Struktur Molekul 2D

Berat 136.1115
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

605 Data
Deferasirox The serum concentration of Hypoxanthine can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Hypoxanthine can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Hypoxanthine can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Hypoxanthine can be decreased when it is combined with Teriflunomide.
Regadenoson Hypoxanthine may decrease effectiveness of Regadenoson as a diagnostic agent.
Adalimumab The serum concentration of Hypoxanthine can be decreased when it is combined with Adalimumab.
Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Hypoxanthine.
Allopurinol The serum concentration of Hypoxanthine can be increased when it is combined with Allopurinol.
Carbamazepine The serum concentration of Hypoxanthine can be decreased when it is combined with Carbamazepine.
Cimetidine The metabolism of Hypoxanthine can be decreased when combined with Cimetidine.
Disulfiram The serum concentration of Hypoxanthine can be increased when it is combined with Disulfiram.
Febuxostat The serum concentration of the active metabolites of Hypoxanthine can be increased when Hypoxanthine is used in combination with Febuxostat.
Fluvoxamine The metabolism of Hypoxanthine can be decreased when combined with Fluvoxamine.
Formoterol The risk or severity of hypokalemia can be increased when Hypoxanthine is combined with Formoterol.
Indacaterol The risk or severity of adverse effects can be increased when Hypoxanthine is combined with Indacaterol.
Isoniazid The serum concentration of Hypoxanthine can be increased when it is combined with Isoniazid.
Lithium citrate The serum concentration of Lithium citrate can be decreased when it is combined with Hypoxanthine.
Lithium carbonate The serum concentration of Lithium carbonate can be decreased when it is combined with Hypoxanthine.
Lithium hydroxide The serum concentration of Lithium hydroxide can be decreased when it is combined with Hypoxanthine.
Mexiletine The metabolism of Hypoxanthine can be decreased when combined with Mexiletine.
Olodaterol Hypoxanthine may increase the hyperkalemic activities of Olodaterol.
Pancuronium The therapeutic efficacy of Pancuronium can be decreased when used in combination with Hypoxanthine.
Pentoxifylline The serum concentration of Hypoxanthine can be increased when it is combined with Pentoxifylline.
Phenytoin The serum concentration of Hypoxanthine can be decreased when it is combined with Phenytoin.
Fosphenytoin The serum concentration of Hypoxanthine can be decreased when it is combined with Fosphenytoin.
Propafenone The serum concentration of Hypoxanthine can be increased when it is combined with Propafenone.
Quinine The serum concentration of Hypoxanthine can be increased when it is combined with Quinine.
Quinidine The serum concentration of Hypoxanthine can be increased when it is combined with Quinidine.
Riociguat Hypoxanthine may increase the hypotensive activities of Riociguat.
Thiabendazole The metabolism of Hypoxanthine can be decreased when combined with Thiabendazole.
Ticlopidine The metabolism of Hypoxanthine can be decreased when combined with Ticlopidine.
Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Hypoxanthine.
Probenecid The serum concentration of Hypoxanthine can be increased when it is combined with Probenecid.
Abiraterone The serum concentration of Hypoxanthine can be increased when it is combined with Abiraterone.
Isoprenaline The serum concentration of Hypoxanthine can be decreased when it is combined with Isoprenaline.
Cyproterone acetate The metabolism of Hypoxanthine can be increased when combined with Cyproterone acetate.
Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Hypoxanthine.
Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Hypoxanthine.
Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Hypoxanthine.
Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Hypoxanthine.
Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Hypoxanthine.
Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Hypoxanthine.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Hypoxanthine.
Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Hypoxanthine.
Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Hypoxanthine.
Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Hypoxanthine.
Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Hypoxanthine.
Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Hypoxanthine.
Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Hypoxanthine.
Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Hypoxanthine.
Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Hypoxanthine.
Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Hypoxanthine.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Hypoxanthine.
Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Hypoxanthine.
Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Hypoxanthine.
Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Hypoxanthine.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Hypoxanthine.
Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Hypoxanthine.
Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Hypoxanthine.
Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Hypoxanthine.
Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Hypoxanthine.
Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Hypoxanthine.
Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Hypoxanthine.
MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Hypoxanthine.
Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Hypoxanthine.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Hypoxanthine.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Hypoxanthine.
Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Hypoxanthine.
Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Hypoxanthine.
Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Hypoxanthine.
Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Hypoxanthine.
Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Hypoxanthine.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Hypoxanthine.
Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Hypoxanthine.
Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Hypoxanthine.
Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Hypoxanthine.
Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Hypoxanthine.
Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Hypoxanthine.
Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Hypoxanthine.
Hydroxyamphetamine The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Hypoxanthine.
Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Hypoxanthine.
Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Hypoxanthine.
Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Hypoxanthine.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Hypoxanthine.
Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Hypoxanthine.
Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Hypoxanthine.
Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Hypoxanthine.
Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Hypoxanthine.
Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Hypoxanthine.
Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Hypoxanthine.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Hypoxanthine.
Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Hypoxanthine.
Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Hypoxanthine.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Hypoxanthine.
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Hypoxanthine.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Hypoxanthine.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Hypoxanthine.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Hypoxanthine.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Hypoxanthine.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Hypoxanthine.

Target Protein

Purine nucleoside phosphorylase PNP

Referensi & Sumber

Synthesis reference: Alvin J. Glasky, Heinrich Bollinger, Hans Rudolf Muller, "Methods of synthesis for 9-substituted hypoxanthine derivatives." U.S. Patent US06849735, issued February 01, 2005.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul